Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ixekizumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Ixekizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixekizumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Ixekizumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixekizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
October 16, 2023
Lead Product(s) : Ixekizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixekizumab
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 12, 2023
Lead Product(s) : Ixekizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixekizumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eli Lilly Forays Into Dermatological Space with Launch of Psoriasis Drug
Details : Copellor (ixekizumab) is a human IgG mAb that selectively binds to IL-17A and prevents IL-17A binding to IL-17 receptor. Thus, this attenuates an inflammatory response mediated by interleukin 17A. It is indicated treat moderate-to-severe plaque psoriasis...
Product Name : Taltz
Product Type : Antibody
Upfront Cash : Inapplicable
March 14, 2023
Lead Product(s) : Ixekizumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixekizumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The new Taltz (Ixekizumab) formulation significantly reduced injection site pain experienced by some people immediately following injection as shown by an 86% decrease in a visual analog scale (VAS) of pain versus the original formulation.
Product Name : Taltz
Product Type : Antibody
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Ixekizumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixekizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis
Details : Undisclosed
Product Name : Taltz
Product Type : Antibody
Upfront Cash : Inapplicable
April 04, 2022
Lead Product(s) : Ixekizumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixekizumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Through clinical trial meta-analysis and real-world evidence, Eli Lilly Taltz® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderate to severe plaque psoriasis.
Product Name : Taltz
Product Type : Antibody
Upfront Cash : Inapplicable
April 23, 2021
Lead Product(s) : Ixekizumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixekizumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The U.S FDA has approved a supplemental Biologics License Application for Taltz® (ixekizumab) injection, 80 mg/mL for the treatment of pediatric patients (ages 6 to under 18) with moderate to severe plaque psoriasis who are candidates for systemic thera...
Product Name : Taltz
Product Type : Antibody
Upfront Cash : Inapplicable
March 30, 2021
Lead Product(s) : Ixekizumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ixekizumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 89 per cent of patients treated with Taltz achieved PASI 75 compared to 25 per cent of patients treated with placebo. 81 per cent of patients treated with Taltz achieved sPGA 0,1 compared to 11 per cent of patients treated with placebo.
Product Name : Taltz
Product Type : Antibody
Upfront Cash : Inapplicable
February 04, 2021
Lead Product(s) : Ixekizumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable